TransMedics Group Inc (TMDX)
80.01
+0.67
(+0.84%)
USD |
NASDAQ |
Jun 08, 16:00
80.02
+0.01
(+0.01%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 2.605B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 187.2% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 20.57 |
| Price to Book Value | 13.52 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.3053 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. |
| URL | https://www.transmedics.com |
| Investor Relations URL | https://investors.transmedics.com/ |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Medical Devices |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Aug. 01, 2023 (est.) |
| Last Earnings Release | May. 01, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. |
| URL | https://www.transmedics.com |
| Investor Relations URL | https://investors.transmedics.com/ |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Medical Devices |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Aug. 01, 2023 (est.) |
| Last Earnings Release | May. 01, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |